Sheller in Chronicle of Higher Education on Major Drug Fraud
The Chronicle of Higher Education 2013-11-08 Federal prosecutors on Thursday concluded another multibillion-dollar settlement with a major pharmaceutical company accused of illegally marketing its drugs. In this case, the company was Johnson & Johnson, the total payment was $2.2-billion, and the key drug was Risperdal, which was approved by federal regulators to treat schizophrenia in […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
Sheller settles Whistleblower UMass medical billing fraud case for 66k
The Boston Globe 2013-08-22 Worcester’s UMass Memorial Medical Center has settled fraud charges with the attorney general in a whistleblower case alleging that it improperly sent bills for uninsured patients to a homeless shelter, so it could tap the state for payments. On dozens of occasions, the hospital sent unpaid bills for emergency care to […]
Number One in Pennsylvania for Verdicts and Settlements 2014
2014-12-19 The $2.2 Billion settlement with Johnson & Johnson Leads the Pack The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. J&J paid the […]
Sheller Spars With FDA
Lawyer Spars With FDA Over J&J Risperdal Court Documents by Ed Silverman, Pharmalot In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as […]
Sheller in Philadelphia Inquirer “FDA Slow to Ask J&J for Drug Data”
The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia lawyer says in letters to the federal agency, and the company should allow those alleging harm from the medicines to release information […]
Sheller on American Law Journal TV discussing FDA and Pharma Executives,
The American Law Journal 2013-06-16 Attorney Stephen Sheller sparred with pharmaceutical defense attorney Hope Freiwald of Dechert law firm on the television program The American Law Journal. The attorneys, joined by Pharmalot author Ed Silverman, Atlanta pharmaceutical product liability attorney Matthew Harman in a program moderated by attorney Christopher Naughton discussed the FDA and drug […]
Sheller in Philadelphia Inquirer “High Court Sides with Philadelphia Drug Firm”
2013-06-25 In a case involving a Philadelphia company, a divided U.S. Supreme Court ruled Monday that federal pharmaceutical laws preempt a person’s ability to sue in state court alleging that a generic drug is designed badly and therefore is dangerous. The court’s 5-4 decision in Mutual Pharmaceutical Co. v. Bartlett is a victory for the […]
SuperLawyers 2013: seven Sheller, P.C. attorneys honored
2013-05-17 [pdf-embedder url=”http://sheller.com/wp-content/uploads/2013/05/Sheller_PASLRS13_FINAL.pdf”] The law firm of Sheller, P.C. announces the selection of six attorneys as Pennsylvania SuperLawyers® and one as Pennsylvania Rising Star for 2013. Stephen A. Sheller is once again honored for the tenth straight year, and for the fourth year as a Top 100 Philadelphia and Top 100 Pennsylvania SuperLawyers®. Also for […]
Sheller Gift Establishes Social Justice Center at Temple University Beasley School of Law
